ImmunityBio reports a GAAP loss of $0.62 per share as revenue reaches $44.2M, exceeding forecasts by $0.26M.
ImmunityBio reported a GAAP loss of $0.62 per share for the quarter, missing estimates by $0.55. The wider-than-expected loss reflects increased R&D and operational costs during the period.
Revenue totaled $44.2M, surpassing expectations by $0.26M. Analysts had anticipated a narrower loss and slightly lower revenue, based on prior quarter performance and industry trends.
Shares showed limited movement in after-hours trading as investors weighed the earnings miss against the revenue beat.